Adam Hammett
Family · Spartanburg, SCNPI 1881005825
Payments from drug & device makers
Across 265 payments — averaging $29.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- AstraZeneca$2K
- AbbVie$909
- Amgen$724
- Lilly USA, LLC$332
- Novo Nordisk$272
- plus $2K from 27 others
What the payments were for
- Consulting fees$2,09527%
- Food & beverage$5,75573%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 3 | $1,953 |
| AstraZeneca | 60 | $1,948 |
| AbbVie | 55 | $909 |
| Amgen | 25 | $724 |
| Lilly USA, LLC | 22 | $332 |
| Novo Nordisk | 13 | $272 |
| Pfizer | 11 | $202 |
| Sanofi-aventis U.S. LLC | 11 | $178 |
| GSK | 6 | $174 |
| Boehringer Ingelheim | 6 | $155 |
| Exact Sciences | 6 | $95 |
| Merck | 6 | $92 |
| Amarin Pharma, Inc. | 6 | $86 |
| Verona Pharma, Inc. | 1 | $86 |
| Johnson & Johnson | 5 | $81 |
| Novartis | 4 | $77 |
| Indivior Inc. | 3 | $67 |
| Alkermes, Inc. | 2 | $48 |
| Abbott | 2 | $46 |
| Lucid Diagnostics Inc. | 2 | $43 |
| Dexcom, Inc. | 2 | $42 |
| Alk-abello, Inc | 2 | $30 |
| Organon | 2 | $29 |
| Astellas Pharma US Inc | 1 | $24 |
| Tris Pharma Inc | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Edwards Lifesciences | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Corium, LLC | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $14 |
| Antares Pharma, Inc. | 1 | $13 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,850 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 151 | $176,802 |
| MounjaroTirzepatide | 115 | $142,431 |
| JardianceEmpagliflozin | 58 | $85,840 |
| XareltoRivaroxaban | 49 | $69,496 |
| Xigduo XrDapaglifloz Propaned/Metformin | 61 | $62,156 |
| GlyxambiEmpagliflozin/Linagliptin | 46 | $59,674 |
| OzempicSemaglutide | 38 | $58,915 |
| VascepaIcosapent Ethyl | 65 | $45,804 |
| ProliaDenosumab | 28 | $42,479 |
| EntrestoSacubitril/Valsartan | 28 | $39,747 |
| TrulicityDulaglutide | 29 | $35,804 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $35,602 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $33,922 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 21 | $27,179 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 25 | $27,140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,948 | $219,937207 claims |
| Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr, Synjardy Xr | $155 | $199,239155 claims |
| Lilly USA, LLCMounjaro, Trulicity | $332 | $178,236144 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $272 | $86,09459 claims |
| Johnson & JohnsonXarelto | $81 | $69,49649 claims |
| AmgenProlia | $724 | $42,47928 claims |
| NovartisEntresto | $77 | $39,74728 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $26,07224 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $178 | $25,83022 claims |
| AbbVieVraylar | $909 | $23,17518 claims |
| GSKShingrix | $174 | $2,02411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.
Other family in Spartanburg
- Ashley McKinneySpartanburg$16K
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.